Eli Lilly to Pay $1.42 Billion to Settle Zyprexa Probe

Jan. 15, 2009
Fine is largest criminal fine for an individual corporation ever imposed in a U.S. criminal prosecution

Eli Lilly pleaded guilty to violating U.S. law in its marketing of anti-psychotic drug Zyprexa and will pay $1.42 billion to settle criminal and civil allegations, officials said on Jan. 15.

Eli Lilly said it had entered a misdemeanor plea for violation of federal law in its off-label promotion of Zyprexa between September 1999 and March 2001 and agreed to pay $615 million.

The Justice Department said the criminal fine of $515 million was the largest ever in a health care case, and the largest criminal fine for an individual corporation ever imposed in a U.S. criminal prosecution of any kind. Lilly also agreed to forfeit $100 million in the settlement.

Officials said so-called "off label" use of drugs was a serious legal issue. "Off-label promotion of pharmaceutical drugs is a serious crime because it undermines the FDA's role in protecting the American public by determining that a drug is safe and effective for a particular use before it is marketed," said Gregory Katsas, assistant attorney general.

The company said it had admitted in its plea that it had promoted Zyprexa in elderly populations as treatment for dementia, including Alzheimer's dementia, "although Zyprexa is not approved for such uses."

The company did not admit the alleged wrongdoing in the civil allegations.

Copyright Agence France-Presse, 2009

Popular Sponsored Recommendations

Taking Control of Inbound Supply Chains

May 22, 2023
Companies can be more efficient when they execute more control over inbound transportation. Penske Logistics has pioneered inbound strategies for over 30 years and has the scale...

A 3D Look at the Future of Machine Imaging Systems

Dec. 8, 2022
In this Ask the Expert we discuss the latest developments in 3D vision systems and how they’re becoming increasingly important across a wide range of industrial applications, ...

Autonomous Operations: A Powerful Solution to Unprecedented Times

June 17, 2021
Yokogawa, a company on the leading edge of industrial automation, provides insight into the profound benefits of autonomous operations in a post-pandemic world.

Manufacturing Performance Benchmark Report

Sept. 6, 2021
To overcome today’s challenges and meet goals and milestones for the future, organizations must operate at the highest level of performance. But unfortunately, not every company...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!